| Analysis | Metabolite Name | Measured Value | Units | Strain | Treatment |
|---|---|---|---|---|---|
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 7290 | Peak area | CRBN -/- | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 8640 | Peak area | CRBN +/+ | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 8900 | Peak area | CRBN -/- | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 9130 | Peak area | CRBN -/- | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 10000 | Peak area | CRBN +/+ | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 11100 | Peak area | CRBN -/- | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 11200 | Peak area | CRBN -/- | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 11900 | Peak area | CRBN +/+ | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 13800 | Peak area | CRBN +/+ | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 14600 | Peak area | CRBN +/+ | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 14800 | Peak area | CRBN -/- | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 14800 | Peak area | CRBN +/+ | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 18500 | Peak area | CRBN -/- | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 19400 | Peak area | CRBN -/- | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 19700 | Peak area | CRBN +/+ | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 20300 | Peak area | CRBN -/- | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 23300 | Peak area | CRBN +/+ | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 25100 | Peak area | CRBN -/- | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 25800 | Peak area | CRBN -/- | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 27200 | Peak area | CRBN -/- | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 32700 | Peak area | CRBN -/- | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 34600 | Peak area | CRBN -/- | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 47200 | Peak area | CRBN -/- | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 51700 | Peak area | CRBN +/+ | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 53200 | Peak area | CRBN -/- | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 53400 | Peak area | CRBN -/- | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 61300 | Peak area | CRBN +/+ | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 64800 | Peak area | CRBN +/+ | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 78400 | Peak area | CRBN -/- | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 88000 | Peak area | CRBN +/+ | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 95800 | Peak area | CRBN -/- | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 121000 | Peak area | CRBN -/- | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 121000 | Peak area | CRBN +/+ | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 148000 | Peak area | CRBN -/- | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 160000 | Peak area | CRBN +/+ | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 173000 | Peak area | CRBN -/- | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 432000 | Peak area | CRBN +/+ | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 463000 | Peak area | CRBN +/+ | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 590000 | Peak area | CRBN -/- | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 694000 | Peak area | CRBN -/- | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 704000 | Peak area | CRBN +/+ | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 736000 | Peak area | CRBN +/+ | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 884000 | Peak area | CRBN -/- | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 933000 | Peak area | CRBN -/- | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 988000 | Peak area | CRBN -/- | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 1040000 | Peak area | CRBN +/+ | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 1050000 | Peak area | CRBN +/+ | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 1460000 | Peak area | CRBN +/+ | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 1480000 | Peak area | CRBN +/+ | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 2560000 | Peak area | CRBN -/- | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 2570000 | Peak area | CRBN -/- | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 3690000 | Peak area | CRBN +/+ | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 3930000 | Peak area | CRBN -/- | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 4390000 | Peak area | CRBN +/+ | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 4870000 | Peak area | CRBN +/+ | unstimulated |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 6550000 | Peak area | CRBN +/+ | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 13600000 | Peak area | CRBN +/+ | anti-CD3 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 18500000 | Peak area | CRBN +/+ | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 19300000 | Peak area | CRBN +/+ | anti-CD3 & anti-CD28 stimulation |
| NEGATIVE ION MODE | 3-SULFINO-L-ALANINE | 25100000 | Peak area | CRBN +/+ | anti-CD3 & anti-CD28 stimulation |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|